Rituximab plus Ifosfamide, Carboplatin and Etoposide for T-Cell/Histiocyte-Rich B-Cell Lymphoma Arising in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

Publisher： Karger

E-ISSN： 1662-6575|5|2|413-419

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.5, Iss.2, 2012-08, pp. : 413-419

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 3, 2015-05 ,pp. : 415-422

John Wiley & Sons Inc

Access to resources Recommend Favorite

Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?

By  

Acta Haematologica, Vol. 134, Iss. 3, 2015-05 ,pp. : 187-192

Karger

Access to resources Recommend Favorite

What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?

By  

Acta Haematologica, Vol. 134, Iss. 3, 2015-05 ,pp. : 185-186

Karger

Access to resources Recommend Favorite

Identifying racial differences in nodular lymphocyte‐predominant Hodgkin lymphoma

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3387-3389

John Wiley & Sons Inc

Access to resources Recommend Favorite

Matched-Pair Analysis Comparing the Outcomes of T Cell/Histiocyte-Rich Large B Cell Lymphoma and Diffuse Large B Cell Lymphoma in Patients Treated with Rituximab-CHOP

By  

Acta Haematologica, Vol. 131, Iss. 3, 2013-10 ,pp. : 156-161

Karger

Access to resources Recommend Favorite